Literature DB >> 7036163

Immunosuppressive effect of bredinin in the management of patients with renal transplantation.

R Kusaba, O Otubo, H Sugimoto, I Takahashi, Y Yamada, J Yamauchi, N Akiyama, T Inou.   

Abstract

Clinical effects of bredinin were evaluated in 18 renal transplant patients. Of 12 cases in which administration of azathioprine was suspended due to liver dysfunction and leucopenia, treatment with bredinin resulted in amelioration of these symptoms without harm to the transplanted kidneys in 10 cases. In six other cases, bredinin was used from the time of renal transplantation, and the postoperative course in four of these cases was uneventful, enabling these patients to return to society. The remaining two patients have had to undergo haemodialysis again as their transplanted kidneys failed to function and they showed severe stomatitis in the early postoperative period. The results of clinical use of bredinin in renal transplant patients suggest that this drug is an effective immunosuppressive agent which is without the drawbacks seen with azathioprine. Nonetheless, one must bear in mind that the function of the transplanted kidney should be evaluated carefully before using this drug.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7036163

Source DB:  PubMed          Journal:  Proc Eur Dial Transplant Assoc        ISSN: 0071-2736


  4 in total

1.  Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.

Authors:  Shuichiro Fujinaga; Kazunari Kaneko; Yoshiyuki Ohtomo; Hitohiko Murakami; Masaru Takada; Shunji Akashi; Mayako Hira; Yuichiro Yamashiro
Journal:  Pediatr Nephrol       Date:  2005-07-15       Impact factor: 3.714

2.  Inhibition of cyclin A gene expression in human B cells by an immunosuppressant mizoribine.

Authors:  S Hirohata; K Nakanishi; T Yanagida
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

3.  Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine.

Authors:  L A Turka; J Dayton; G Sinclair; C B Thompson; B S Mitchell
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 4.  Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.

Authors:  Kyoung Hee Han; Seong Heon Kim
Journal:  Biomed Res Int       Date:  2016-04-18       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.